U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07554508) titled 'Belzutifan VHL RCC HK Prospective Registry' on April 21.
Brief Summary: This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.
Study Start Date: May, 2026
Study Type: OBSERVATIONAL
Condition:
VHL - Von Hippel-Lindau Syndrome
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chinese University of Hong Kong
Information provided by (Responsible Party): NG Chi Fai, Chinese University of Hong Kong
Published by HT Digital Content Services with permission from Health Daily Digest....